Raymond James upgraded UnitedHealth to Outperform ahead of April 21 earnings, and shares surged another 11% after hours when Medicare Advantage rates for 2027 came in better than expected.
UnitedHealth Group is heading into its first-quarter earnings report on the back of two significant tailwinds, as a well-timed analyst upgrade and a favorable government rate decision for Medicare Advantage plans combined to send shares sharply higher today. The stock gained approximately 1.2% earlier in the session following a Raymond James upgrade, then surged an additional 11% in after-hours trading after the Centers for Medicare and Medicaid Services announced a 2.48% rate increase for private insurers in 2027, a figure that came in meaningfully better than the preliminary rates the agency had proposed back in January.
Raymond James makes its move ahead of earnings
The upgrade from Raymond James arrived on April 1, when analyst John Ransom elevated UnitedHealth from Market Perform to Outperform and set a price target of $330. Ransom’s core argument is that Wall Street has been underestimating the company’s earnings potential, particularly its capacity to improve profitability through operational efficiency. His analysis suggests that every 100-basis-point improvement in general and administrative costs could contribute approximately $3.80 per share to the company’s bottom line, a figure that implies meaningful upside if management executes on its cost reduction priorities.
The upgrade moved the stock on April 2, pushing shares to an intraday high of $279.04 before they settled at $277.30, a gain of roughly 1.2% on the day.
Ransom also pointed to improving visibility into the margins of Optum Health, UnitedHealth’s healthcare services division. While margin growth at Optum may appear flat in the current year, Raymond James views the underlying trajectory as positive, particularly as the company continues to exit underperforming operations. UnitedHealth has already closed or divested several unprofitable clinic locations, a restructuring move expected to reduce margin drag as those exits are completed. Optum’s fee-for-service business, which generates roughly $33 billion in annual revenue, currently operates on single-digit margins, leaving what analysts consider meaningful room for improvement with better execution.
The Medicare rate decision that moved the whole sector
The more dramatic price action came after hours, when the CMS announced its final 2027 payment rates for Medicare Advantage plans. The 2.48% increase for private insurers represented a significant improvement over what the agency had floated in January, and the market reaction across the healthcare sector was immediate and broad.
Five major healthcare companies saw their shares jump in extended trading following the announcement. 1. Humana led the group with a 12% gain, reflecting its heavy exposure to Medicare Advantage as a core business line. 2. UnitedHealth climbed 11%. 3. CVS Health advanced 9%. 4. Elevance Health rose 5%. Hospital operators also benefited, with 5. Molina Healthcare gaining 7% and 6. Centene rising 4%.
The Medicare Advantage rate decision carries outsized importance for UnitedHealth because the program has been one of the primary sources of pressure on the stock in 2026. The company’s shares had fallen nearly 17% year to date heading into today, weighed down by conservative forward guidance and persistent challenges in the Medicare Advantage segment that pushed the stock below the price Berkshire Hathaway paid for its stake, prompting debate about whether the selloff had created a buying opportunity.
What Wall Street expects when earnings arrive
UnitedHealth is scheduled to report first-quarter results before the market opens on April 21. Analysts expect adjusted earnings per share of $6.69 for the quarter, representing an 8% decline from the same period a year ago. Revenue is forecast at $109.58 billion, roughly flat year over year. Options markets are pricing in a move of approximately 9% in either direction following the report, reflecting the level of uncertainty that still surrounds the company’s near-term performance.
The broader analyst consensus on UnitedHealth remains firmly constructive despite the year-to-date decline. Based on TipRanks data compiled April 1, the stock carries a Strong Buy rating supported by 17 Buy recommendations, three Hold ratings and zero Sell ratings. The average 12-month price target sits at $366.47, implying roughly 35% upside from recent levels, with the most optimistic analyst projecting the stock reaching $440.
Risks that remain on the radar
Not every voice on Wall Street shares that level of enthusiasm. Leerink flagged exposure to Risk Adjustment Data Validation audits, the government’s mechanism for reviewing the accuracy of Medicare Advantage reimbursements, as a material headwind. A pending Ninth Circuit ruling on UnitedHealth’s preemption defense in ongoing litigation could also expand the company’s legal liability if the decision goes against it, adding a layer of legal uncertainty to an already complex setup heading into earnings.
Institutional investors hold approximately 87.9% of the float, with prominent positions held by Norges Bank, Capital Research Global Investors, Berkshire Hathaway and Dodge & Cox, which doubled its position last year. The company pays an annualized dividend of $8.84 per share, yielding approximately 3.2%, and recently entered the top 10 holdings of the Schwab U.S. Dividend Equity ETF despite the year-to-date decline.
SOURCE: MEXC
Disclaimer: This article is for informational purposes only and does not constitute financial advice. The author and publication are not registered investment advisors and do not provide personalized investment recommendations.